Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients
First, the investigators examined the functional relevance of serotonin transporter polymorphisms by quantifying the activity of serotonin transporter in blood platelets of genotyped healthy volunteers and patients with major depression.
Second, the investigators studied response to SSRIs in relation to 5-HTTLPR genotype and also to the functional expression of 5-HTT in platelets.
|Depression Continuous Antidepressant Abuse Adverse Reaction to Drug||Drug: SSRI treated group|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients|
- Antidepressant Response at 2,4,6 weeks [ Time Frame: 6 weeks ]
- Biological value at 0 and 6 weeks [ Time Frame: 6weeks ]
|Study Start Date:||October 1999|
|Estimated Study Completion Date:||December 2016|
|Primary Completion Date:||December 2003 (Final data collection date for primary outcome measure)|
Experimental: SSRI treated group
SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline
Drug: SSRI treated group
characterize in arm of a study (SSRI treated group)
The purpose of this study is
- to determine whether serotonin transporter genotypic or functional differences between depressive patients and normal controls were existed.
- to determine the relationship between serotonin transporter polymorphisms and serotonin transporter functional expression.
- to determine whether genomic or functional differences between drug responders and nonresponders predict the response of antidepressant
Please refer to this study by its ClinicalTrials.gov identifier: NCT01237275
|Korea, Republic of|
|Samsung Medical Center|
|Kangnam, Seoul, Korea, Republic of|
|Principal Investigator:||Doh Kwan Kim, M.D., Ph.D.||Samsung Medical Center|